Subtopic Deep Dive
Herpes Zoster Vaccination Efficacy
Research Guide
What is Herpes Zoster Vaccination Efficacy?
Herpes Zoster Vaccination Efficacy evaluates the effectiveness of vaccines like Zostavax and Shingrix in preventing shingles (herpes zoster) and postherpetic neuralgia (PHN) in older adults and immunocompromised populations.
Key studies include RCTs showing HZ/su vaccine efficacy of over 90% in adults aged 50+ (Lal et al., 2015, 1349 citations) and sustained protection in those 70+ (Cunningham et al., 2016, 995 citations). Real-world data and systematic reviews quantify HZ incidence and complications globally (Kawai et al., 2014, 878 citations). Over 10 foundational and recent papers with 300-1349 citations establish evidence for policy recommendations (Dooling et al., 2018, 579 citations).
Why It Matters
Shingrix reduces HZ risk by 97% and PHN by 91% in adults 50+, informing CDC recommendations for universal vaccination in adults 50+ (Lal et al., 2015; Cunningham et al., 2016; Dooling et al., 2018). In immunocompromised patients like those on tofacitinib for RA, HZ risk rises 3-4 fold, making vaccine efficacy critical for risk mitigation (Winthrop et al., 2014). Global HZ incidence of 3-5 cases per 1000 person-years drives immunization policies, cutting PHN burden which impairs quality-of-life for months (Kawai et al., 2014; Johnson et al., 2010).
Key Research Challenges
Waning Vaccine Efficacy
Zostavax efficacy drops from 67% at year 3 to 40% by year 10, requiring long-term persistence studies (Morrison et al., 2014). HZ/su shows better durability but needs decade-long follow-up in diverse populations. Real-world waning complicates policy for boosters.
Immunocompromised Efficacy
Limited RCT data exist for high-risk groups like RA patients on tofacitinib, where HZ incidence triples (Winthrop et al., 2014). Vaccine response may be blunted by immunosuppression, demanding targeted trials. Balancing risks versus benefits remains unresolved.
Global Incidence Variability
HZ rates vary 3-12 per 1000 person-years by region, complicating universal vaccine strategies (Kawai et al., 2014). Age-specific PHN risks differ, with gaps in low-resource settings data. Standardization of surveillance hinders modeling.
Essential Papers
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Himal Lal, Anthony L. Cunningham, Olivier Godeaux et al. · 2015 · New England Journal of Medicine · 1.3K citations
The HZ/su vaccine significantly reduced the risk of herpes zoster in adults who were 50 years of age or older. Vaccine efficacy in adults who were 70 years of age or older was similar to that in th...
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Anthony L. Cunningham, Himal Lal, Martina Kovac et al. · 2016 · New England Journal of Medicine · 995 citations
In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 Clinic...
Systematic review of incidence and complications of herpes zoster: towards a global perspective
K. Kawai, Berhanu G. Gebremeskel, Camilo J. Acosta · 2014 · BMJ Open · 878 citations
Objective The objective of this study was to characterise the incidence rates of herpes zoster (HZ), also known as shingles, and risk of complications across the world. Design We systematically rev...
Recommendations for the Management of Herpes Zoster
Robert H. Dworkin, Robert W. Johnson, Judith Breuer et al. · 2006 · Clinical Infectious Diseases · 827 citations
The objective of this article is to provide evidence-based recommendations for the management of patients with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact o...
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
Kathleen Dooling, Angela Guo, Manisha Patel et al. · 2018 · MMWR Morbidity and Mortality Weekly Report · 579 citations
On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein ...
Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years
Ken Schmader, Myron J. Levin, J. W. Gnann et al. · 2012 · Clinical Infectious Diseases · 428 citations
NCT00534248.
The impact of herpes zoster and post-herpetic neuralgia on quality-of-life
Robert W. Johnson, Didier Bouhassira, George Kassianos et al. · 2010 · BMC Medicine · 380 citations
A vaccination scheme may positively impact the incidence and course of HZ disease, thereby improving patients' quality-of-life.
Reading Guide
Foundational Papers
Start with Kawai et al. (2014, 878 citations) for global HZ incidence baseline, then Dworkin et al. (2006, 827 citations) for management context informing vaccination needs; Schmader et al. (2012, 428 citations) establishes Zostavax efficacy in 50-59 year-olds.
Recent Advances
Lal et al. (2015, 1349 citations) for Shingrix RCT in 50+; Cunningham et al. (2016, 995 citations) for 70+ efficacy; Dooling et al. (2018, 579 citations) for policy integration.
Core Methods
RCTs measure vaccine efficacy as (1 - [HZ cases vaccinated / HZ cases control]) x 100; burden of illness endpoints track PHN duration/severity (Lal et al., 2015); systematic reviews pool incidence rates via random-effects meta-analysis (Kawai et al., 2014).
How PapersFlow Helps You Research Herpes Zoster Vaccination Efficacy
Discover & Search
Research Agent uses searchPapers and citationGraph to map ZOE-50/70 trials from Lal et al. (2015), revealing 1349 citations and forward links to Dooling et al. (2018) ACIP guidelines. exaSearch uncovers real-world studies beyond RCTs; findSimilarPapers links Kawai et al. (2014) global review to Winthrop et al. (2014) immunocompromised risks.
Analyze & Verify
Analysis Agent applies readPaperContent to extract efficacy endpoints from Lal et al. (2015), then verifyResponse with CoVe chain-of-verification flags contradictions in waning claims versus Morrison et al. (2014). runPythonAnalysis computes meta-analysis of HZ incidence rates from Kawai et al. (2014) using pandas/NumPy, with GRADE grading for RCT evidence quality.
Synthesize & Write
Synthesis Agent detects gaps like long-term immunocompromised data via contradiction flagging between Winthrop et al. (2014) and Lal et al. (2015); Writing Agent uses latexEditText, latexSyncCitations for Shingrix review manuscript, latexCompile for PDF, exportMermaid for efficacy persistence timelines.
Use Cases
"Extract HZ incidence rates from Kawai 2014 and plot age-stratified meta-analysis."
Research Agent → searchPapers('Kawai herpes zoster incidence') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas groupby age, matplotlib barplot) → CSV export of global rates summary.
"Draft LaTeX section on Shingrix efficacy with citations from Lal 2015 and Cunningham 2016."
Research Agent → citationGraph('Lal 2015') → Synthesis Agent → gap detection → Writing Agent → latexEditText('efficacy section') → latexSyncCitations → latexCompile → PDF with inline citations.
"Find GitHub repos analyzing Zostavax long-term data from Morrison 2014."
Research Agent → searchPapers('Morrison zoster vaccine persistence') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(jupyter survival analysis) → runPythonAnalysis(replicate waning curves).
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ HZ vaccine papers) → citationGraph → GRADE grading → structured report on efficacy by age/immunostatus. DeepScan applies 7-step analysis with CoVe checkpoints to verify PHN reduction claims across Lal/Cunningham trials. Theorizer generates hypotheses on booster timing from waning data in Morrison et al. (2014).
Frequently Asked Questions
What is Herpes Zoster Vaccination Efficacy?
It measures vaccines like Shingrix preventing HZ and PHN, with 97% efficacy in 50+ adults from ZOE-50 RCT (Lal et al., 2015).
What methods assess efficacy?
RCTs like ZOE-50/70 use confirmed HZ cases for vaccine efficacy calculation; real-world studies track incidence via registries (Lal et al., 2015; Cunningham et al., 2016).
What are key papers?
Lal et al. (2015, 1349 citations) shows 97.2% efficacy; Cunningham et al. (2016, 995 citations) confirms 89.8% in 70+; Dooling et al. (2018) provides ACIP recommendations.
What open problems exist?
Waning efficacy beyond 10 years (Morrison et al., 2014); efficacy in immunocompromised like RA on tofacitinib (Winthrop et al., 2014); global low-resource data gaps (Kawai et al., 2014).
Research Herpesvirus Infections and Treatments with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Herpes Zoster Vaccination Efficacy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.